Navigation Links
Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
Date:10/22/2013

n 2014: Based on the findings to date in the Phase 1 study of EPZ-5676 in adults, Epizyme plans to initiate a Phase 1 trial of EPZ-5676 in pediatric patients with MLL-r leukemia in the first half of 2014. The study will initially be open in approximately 5-6 investigational sites in the U.S.
  • Broadening Program into AML with MLL-PTD in 2014: Epizyme plans to initiate a clinical study of EPZ-5676 in patients with AML with a genetic alteration called MLL-PTD. MLL-PTD cell lines and animal models exhibit similar sensitivity to DOT1L inhibition as seen in MLL-r pre-clinical studies. This data was presented on October 21, 2013, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. MLL-PTD accounts for an estimated 5-7% of adult AML cases with an estimated annual incidence of 2,300 patients in the major markets (U.S., EU and Japan) and represents a meaningful potential expansion of the clinical opportunity for EPZ-5676.
  • EPZ-6438 Clinical Development – Progress and Plans

  • Initiated Dose Escalation Study: In June 2013 Epizyme announced the enrollment of the first patient in a Phase 1/2 study of EPZ-6438 (referred to as E7438 by Eisai). The Phase 1 dose escalation study is ongoing at two sites in France, and no dose-limiting toxicities have been observed to date. The companies also plan to significantly increase the number of clinical sites in 2014, and to submit an IND in the U.S., in anticipation of the Phase 2 initiation.  
  • Phase 2 Initiation Expected in 2014: With partner Eisai, Epizyme plans to initiate the Phase 2 portion of this study in 2014 after completion of the dose escalation phase. This phase will only enroll patients with non-Hodgkin lymphoma with oncogenic point mutations in EZH2 and is expected to provide an initial assessment of therapeutic effect
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
    2. New Resource Provides Herb Industry With Sources of Quality Specifications
    3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
    4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
    5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
    6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
    7. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
    8. Insmed Incorporated Provides Corporate Update
    9. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
    10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    11. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
    (Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
    (Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
    (Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
    Breaking Biology Technology:3D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
    ... (OTC Bulletin Board: CHBT), a leading Chinese firm ... of,probiotics dietary supplements, today announced it will host ... August 15, 2008, to discuss the Company,s,financial results ... of its fiscal,2009., Hosting the call will ...
    ... Aug. 7 Campbell Alliance, the leading,management consulting ... announced that Nader Naeymi-Rad has been appointed Chief,Operating ... Senior Vice,President and head of the firm,s Brand ... the same title., This new senior executive ...
    ... be Marketed Worldwide, ALEXANDRIA, Va. and ... (SAFRAN Group) the industry leader in multi-biometric,solutions, ... BKYI), a,leader in finger-based biometric identification and ... partnership that combines the,strengths of both companies ...
    Cached Biology Technology:China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 2China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 3Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 2Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 3Sagem Morpho and BIO-key Announce Biometric Partnership Agreement 2Sagem Morpho and BIO-key Announce Biometric Partnership Agreement 3
    (Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
    (Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this market ... systems utilize more than one characteristic of an individual ...
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
    Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
    ... (New York City, October 20, 2011) In the October 20th ... Drs. Claudia Plottel and Martin J. Blaser of the Departments ... the Department of Biology at New York University, present a ... an understanding of the bacteria living in our body, the ...
    ... Inc., a company using its proprietary Protein Design ... announced today the initiation of a Phase 1 ... for the treatment of autoimmune diseases. XmAb5871 uses ... disorders that may avoid some of the side ...
    ... have found that pressure from increasing coastal populations, ship ... are critically threatening the health of the Florida Keys ... sea turtles and coral habitat continue to be at ... findings were released today in the Condition Report 2011 ...
    Cached Biology News:Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases 2NOAA releases status on Florida Keys National Marine Sanctuary marine resources 2
    Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
    ... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
    anti-Lactate Dehydrogenase...
    Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
    Biology Products: